Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

Norlin, Jenny M.; Carlsson, Katarina Steen; Persson, Ulf; Schmitt‐Egenolf, Marcus

doi:10.1159/000345715

Cited by 46 publications

(52 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The initial treatment for mild psoriasis includes topical steroids and phototherapy, whereas the initial treatment for moderate-to-severe psoriasis includes phototherapy and conventional systemic therapy, alone or in combination 37. In the past decade, the development of several drugs, biologics, and non-biologics has substantially improved the outcomes of patients with moderate-to-severe psoriasis 38. These include tumor necrosis factor (TNF)-α inhibitors (adalimumab, etanercept, certolizumab, golimumab, and infliximab), interleukin (IL)-12 and 23 inhibitor (ustekinumab), and IL-17A inhibitors (secukinumab and ixekizumab).…”

Section: Introductionmentioning

confidence: 99%

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative

Colombo

Matteo²,

Martinotti³

et al. 2018

CEOR

View full text Add to dashboard Cite

ObjectiveSecukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes the proinflammatory cytokine IL-17A, has been approved in Europe in 2015 for the treatment of adult patients with moderate-to-severe plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This analysis assessed the budget impact of introduction of secukinumab to the Italian market for all three indications from the perspective of the Italian National Health Service.Materials and methodsA cross-indication budget impact model was developed and included biologic-treated adult patients diagnosed with psoriasis, PsA, and AS. The analyses were conducted over a 3-year time horizon and included direct costs (drug therapy costs, administration costs, diseases-related costs, and adverse events costs). Model input parameters (epidemiology, market share projections, resource use, and costs) were obtained from the published literature and other Italian sources. The robustness of the results was tested via one-way sensitivity analyses: secukinumab cost, secukinumab market share, intravenous administration costs, and adverse events costs were varied by ±10%.ResultsThe total patient population for secukinumab over the 3-year timeframe was projected to be 6,648 in the first year, increasing to 12,001 in the third year, for all three indications combined (psoriasis, PsA, and AS). Compared to a scenario without secukinumab in the market, the introduction of secukinumab in the market for the treatment of psoriasis, PsA, and AS showed a cumulative 3-year incremental budget impact of −5%, corresponding to savings of €66.1 million and per patient savings of about €1,855. The majority of the cost savings came from the adoption of secukinumab in AS (58%), followed by PsA (29%) and psoriasis (13%). Sensitivity analyses confirmed the robustness of the results.ConclusionResults from this cross-indication budget impact model show that secukinumab is a cost-saving option for the treatment of PsA, AS, and psoriasis patients in Italy.

show abstract

Section: Introductionmentioning

confidence: 99%

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative

Colombo

Matteo²,

Martinotti³

et al. 2018

CEOR

View full text Add to dashboard Cite

show abstract

“…Although some articles indicate that the therapy effect should be more robust than it is in the real clinical practice within first 12 weeks. There is a clear benefit for the patient when switching regular systemic therapy for biologics as shown in the analysis of Swedish registry PsoReg [46,47]. Long-term information on efficacy and safety are inconsistent in real life settings.…”

Section: Discussionmentioning

confidence: 99%

Centralised Biological Therapy Registry for Moderate to Severe Plaque Psoriasis – Overview and Methodology

Sutka

Pecova

2016

Acta Medica Martiniana

View full text Add to dashboard Cite

A b s t r a c tThe introduction of new pharmacotherapy entities in the last decade accentuate the necessity to set up treatment guidelines based on real life evidence. Randomized controlled trials remain golden standard of a research. Data derived from studies aiming on daily clinical practice should bring needed, added value. Disease prevalence growth, due to increased life expectancy, better diagnostic procedures and earlier medical intervention, as well as ever growing demand for highly priced, sophistically produced drugs put stress on healthcare budgets even in developed countries. Large databases commonly called -therapy registries are implemented to collect data on therapy effectivity in terms of effectiveness, safety and patient long-term on therapy survival. Registries importance rose together with biological therapies introduction. New in class molecules entered the market conditionally being obliged to provide additional e.g. safety data. Such procedures require involvement of many different professionals, e.g. physicians, professional medical bodies, IT experts, database administrators, statisticians and government institutions. Paper based, followed by computer based forms were distributed among physicians to collect these data. eHealth technologies provide physicians with centralized, more intuitive applications. The particularities of different diagnosis caused great variations within each specific registry launched. Important information was missing since they were pointed out as optional and many were redundant causing frustration among physicians due to inadequate administrative workload. The main objective of this work was to set up the therapy registry standards and procedures. Methodology of "ideal" moderate to severe plaque psoriasis biology therapy registry development, introduction, administration and evaluation was prepared to assist any government institution or professional body when planning registry deployment. Electronic application based on widely used MS Excel platform was developed and installed in the biological therapy centers as a standalone application for the pilot use.

show abstract

“…In previous observational studies, some patients with severe forms of psoriasis were not prescribed biologics, while others who did not fulfill the criteria for moderate-to-severe psoriasis received prescription [7, 8]. Aside from disease severity, a number of factors have been reported to affect the prescription of biologics.…”

Section: Introductionmentioning

confidence: 99%

Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundObservational studies suggest an inequitable prescription of biologics in psoriasis care, which may be attributed to geographical differences in treatment access. Sweden regularly ranks high in international comparisons of equitable healthcare, and is, in connection with established national registries, an ideal country to investigate potential inequitable access.ObjectiveThe aim was to determine whether the opportunity for patients to receive biologics depends on where they receive care.MethodsBiologic-naïve patients enrolled in the Swedish National Register for Systemic Treatment of Psoriasis (PsoReg) from 2008 to 2015 (n = 4168) were included. The association between the likelihood of initiating a biologic and the region where patients received care was analyzed. The strength of the association was adjusted for patient and clinical characteristics, as well as disease severity using logistic regression analysis. The proportion of patients that switched to a biologic (switch rate) and the probability of switch to a biologic was calculated in 2-year periods.ResultsThe national switch rate increased marginally over time from 9.7 to 11.0%, though the uptake varied across regions. Adjusted odds ratios for at least one region were significantly different from the reference region in every 2-year period. During the latest period (2014–2015), the average patient in the lowest prescribing region was nearly 2.5 times less likely to switch as a similar patient in the highest prescribing region.ConclusionsGeographical differences in biologics prescription persist after adjusting for patient characteristics and disease severity. The Swedish example calls for further improvements in delivering equitable psoriasis care.Electronic supplementary materialThe online version of this article (doi:10.1007/s40259-016-0209-y) contains supplementary material, which is available to authorized users.

show abstract

Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

Cited by 46 publications

References 26 publications

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative

Centralised Biological Therapy Registry for Moderate to Severe Plaque Psoriasis – Overview and Methodology

Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients

Contact Info

Product

Resources

About